Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Public ClinicalTrials.gov record NCT04940299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Study identification
- NCT ID
- NCT04940299
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 35 participants
Conditions and interventions
Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Locally Advanced Bladder Carcinoma
- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Renal Pelvis Carcinoma
- Locally Advanced Renal Pelvis Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Locally Advanced Urethral Urothelial Carcinoma
- Malignant Solid Neoplasm
- Metastatic Bladder Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Melanoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Metastatic Urethral Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Stage III Bladder Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Bladder Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Lung Cancer AJCC v6
- Stage IV Renal Pelvis Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Unresectable Melanoma
Interventions
- Ipilimumab Biological
- Nivolumab Biological
- Tocilizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2021
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Mar 5, 2026
2021 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04940299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04940299 live on ClinicalTrials.gov.